Compare FDP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | DNTH |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | FDP | DNTH |
|---|---|---|
| Price | $40.23 | $49.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $71.22 |
| AVG Volume (30 Days) | 210.4K | ★ 810.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.50 | $13.37 |
| 52 Week High | $41.05 | $57.50 |
| Indicator | FDP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 53.85 |
| Support Level | $39.26 | $45.64 |
| Resistance Level | $40.44 | $53.33 |
| Average True Range (ATR) | 1.03 | 3.35 |
| MACD | 0.06 | -0.60 |
| Stochastic Oscillator | 73.20 | 34.82 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.